Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genethon

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

12 comunicati stampa

Guarda tutti i comunicati
10/10/2025
Multimedialità
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Eventi
Fiere
Industria
Data from GNT-018-IDES Trial Supports Feasibility of imlifidase as Pretreatment in Gene Therapy Treatment for Patients With Crigler–Najjar Syndrome Who Are Immune to AAV
Fonte
Genethon
Emittente
Business Wire
1.00
0
09/10/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Web e Social Network
Volontariato/Solidarietà/Non profit
Eventi
Industria
Genethon Confirms 2-Year Efficacy in Duchenne Muscular Dystrophy Patients Treated With Its Low Dose Micro-Dystrophin Gene Therapy (GNT0004) at the ESGCT 32nd Annual Congress
Fonte
Genethon
Emittente
Business Wire
1.00
0
28/07/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Genethon to Launch Pivotal Trial in Europe of GNT0004 a Low-Dose Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
Fonte
Genethon
Emittente
Business Wire
1.00
0
19/06/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Eventi
Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster’s First International Summit, Atamyo Therapeutics’ Progress for LGMDs Highlight Genethon’s Most Recent Newsletter
Fonte
Genethon
Emittente
Business Wire
1.00
0
19/05/2025
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Genethon Presents Two Year Consolidated Results of Its Gene Therapy Trial for Duchenne Muscular Dystrophy: Maintenance of Motor Functions and Significant, Sustained Reduction in CPK Levels in Patients Treated at the Effective Dose at ASGCT 2025
Fonte
Genethon
Emittente
Business Wire
1.00
0
27/02/2025
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Genethon Celebrates Rare Disease Day by Highlighting New Technologies to Advance Gene Therapies and Bring Hope to Millions of Patients Worldwide
Fonte
Genethon
Emittente
Business Wire
1.00
0
19/12/2024
Tecnica
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Volontariato/Solidarietà/Non profit
Industria
A Phase 3 Ready DMD Gene Therapy, a Clinical Trial to Offset AAV Neutralizing Antibodies, and an AI Inspired New Generation of Capsids Highlight Genethon’s 2024 Fall Milestones
Fonte
Genethon
Emittente
Business Wire
1.00
0
03/12/2024
Multimedialità
Industria
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
Fonte
Genethon
Emittente
Business Wire
1.00
0
19/11/2024
Salute
Biotecnologia
Medicina - Varie
Scienza
Farmaceutica
Eventi
Industria
Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago
Fonte
Genethon
Emittente
Business Wire
1.00
0
21/10/2024
Eventi
Fiere
Industria
Tecnica
HIV, AIDS e malattie autoimmuni
Sanità
Famiglia
Biotecnologia
Vetrine/Shopping
Medicina - Varie
Cardiologia
Salute
Giovani
Terza età
Infanzia
Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31st Annual Congress October 22 – 25, 2024 in Rome, Italy
Fonte
Genethon
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0